CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
S1605 SWOG Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Adult CIRB - Late Phase Emphasis
S1607 SWOG A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy Adult CIRB - Late Phase Emphasis
S1608 SWOG Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma Adult CIRB - Late Phase Emphasis
S1609 SWOG DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Adult CIRB - Late Phase Emphasis
S1612 SWOG A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older Adult CIRB - Late Phase Emphasis
S1613 SWOG A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification Adult CIRB - Late Phase Emphasis
S1614 SWOG A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors Cancer Prevention and Control CIRB
S1616 SWOG A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent Adult CIRB - Late Phase Emphasis
S1619 SWOG A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma Adult CIRB - Late Phase Emphasis
S1701 SWOG A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Adult CIRB - Late Phase Emphasis